AUPH News and Press, Aurinia Pharmaceuticals Inc From 01/05/24

Preliminary unaudited total net revenue for the fourth quarter and full year 2023 of approximately $45 million and $176 million Preliminary unaudited net product revenue for the fourth quarter and full year 2023 of approximately $42 million and $159 million Approximately $351 mill...

AUR200, a potent recombinant fusion protein, has a clinically validated MOA with a high affinity for targeting both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand) Upon FDA clearance of the IND, AUR 200 will be studied in a Phase 1 first-in-human trial in healthy v...

2023-12-07 11:16:36 ET Summary Today, we circle back on promising biopharma Aurinia Pharmaceuticals Inc. The company posted better-than-expected Q3 results and has been the subject of more buyout speculation, and had its marketing partner file for approval in Japan for its flagshi...

2023-11-23 02:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-21 10:30:55 ET Aurinia Pharmaceuticals ( NASDAQ: AUPH ) soared 6.7% amid takeover speculation. The Aurinia ( AUPH ) stock surge comes amid a report that a Gilead Sciences ( GILD ) corporate jet made a trip to Aurinia's headquarters in Edmonton, Canada, accord...

2023-11-13 07:11:13 ET More on Aurinia Pharma Aurinia Pharmaceuticals Inc. (AUPH) Q3 2023 Earnings Call Transcript Aurinia Pharmaceuticals: Reassessing As It Gains Traction Aurinia Rides High On Lupkynis, But Not Without Cost (Rating Upgrade) Aurinia Pharma s...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s collaboration partner, Otsuka Pharmaceutical Ltd., filed a new drug application (NDA) for voclosporin for the treatment of lupus nephritis (LN) with the Japanese Ministry of Health, Labo...

A propensity analysis of AURORA 1 suggested that initial therapy with LUPKYNIS ® plus standard of care improved safety and demonstrated earlier reductions in proteinuria when compared to a conventional regimen consisting of higher doses of both mycophenolate mofetil and glucocorticoids a...

Patients treated with LUPKYNIS Ⓡ in a repeat kidney biopsy sub-study achieved improvement in histologic activity with stable chronicity scores and no evidence of chronic injury. A propensity analysis of AURORA 1 suggested that LUPKYNIS Ⓡ plus standard of care improved sa...

2023-11-02 12:06:10 ET Aurinia Pharmaceuticals Inc. (AUPH) Q3 2023 Earnings Conference Call November 02, 2023, 08:30 AM ET Company Participants Jamie Harrell - Investor Relations Peter Greenleaf - Chief Executive Officer Joe Miller - Chief Financial Officer ...